Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCN-01 +/- Gemcitabine/Abraxane in Advanced Solid Tumors
NCT02045602Phase 1Completed
- Sponsor
- Theriva Biologics
- Start
- Jan 2014
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of zabilugene almadenorepvec in solid tumor and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Theriva Biologics. Primary endpoints: Safety and Tolerability by means of Adverse Events (AEs) and laboratory data at 6 months and Recommended Phase 2 Dose at 6 months. Started Jan 2014; status: completed.
02
Drugs
zabilugene almadenorepvec
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02045602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045602.